670 related articles for article (PubMed ID: 27406834)
1. Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future Directions.
Bhalla S; Tremblay D; Mascarenhas J
Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):488-494. PubMed ID: 27406834
[TBL] [Abstract][Full Text] [Related]
2. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
Saussele S; Richter J; Guilhot J; Gruber FX; Hjorth-Hansen H; Almeida A; Janssen JJWM; Mayer J; Koskenvesa P; Panayiotidis P; Olsson-Strömberg U; Martinez-Lopez J; Rousselot P; Vestergaard H; Ehrencrona H; Kairisto V; Machová Poláková K; Müller MC; Mustjoki S; Berger MG; Fabarius A; Hofmann WK; Hochhaus A; Pfirrmann M; Mahon FX;
Lancet Oncol; 2018 Jun; 19(6):747-757. PubMed ID: 29735299
[TBL] [Abstract][Full Text] [Related]
3. Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia.
Caldemeyer L; Akard LP
Leuk Lymphoma; 2016 Dec; 57(12):2739-2751. PubMed ID: 27562641
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice.
Breccia M; Efficace F; Colafigli G; Scalzulli E; Di Prima A; Martelli M; Foà R
Expert Rev Hematol; 2020 Dec; 13(12):1311-1318. PubMed ID: 33205694
[No Abstract] [Full Text] [Related]
5. ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives.
Massimino M; Stella S; Tirrò E; Pennisi MS; Vitale SR; Puma A; Romano C; DI Gregorio S; Tomarchio C; DI Raimondo F; Manzella L
Anticancer Res; 2020 May; 40(5):2457-2465. PubMed ID: 32366389
[TBL] [Abstract][Full Text] [Related]
6. NCCN Guidelines Updates: Discontinuing TKI Therapy in the Treatment of Chronic Myeloid Leukemia.
Shah NP
J Natl Compr Canc Netw; 2019 May; 17(5.5):611-613. PubMed ID: 31117031
[TBL] [Abstract][Full Text] [Related]
7. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G
Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758
[TBL] [Abstract][Full Text] [Related]
8. Treatment-free remission with first- and second-generation tyrosine kinase inhibitors.
Cortes J; Rea D; Lipton JH
Am J Hematol; 2019 Mar; 94(3):346-357. PubMed ID: 30394563
[TBL] [Abstract][Full Text] [Related]
9. How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy.
Rea D; Mahon FX
Br J Haematol; 2018 Jan; 180(1):24-32. PubMed ID: 29048128
[TBL] [Abstract][Full Text] [Related]
10. Is cure for chronic myeloid leukemia possible in the tyrosine kinase inhibitors era?
Bansal A; Radich J
Curr Opin Hematol; 2016 Mar; 23(2):115-20. PubMed ID: 26825700
[TBL] [Abstract][Full Text] [Related]
11. The story of tyrosine kinase inhibitors discontinuation in clinical practice.
Rousselot P
Leuk Lymphoma; 2018 Dec; 59(12):2782-2791. PubMed ID: 29909726
[TBL] [Abstract][Full Text] [Related]
12. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
13. WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors.
Haznedaroğlu İC; Kuzu I; İlhan O
Turk J Haematol; 2020 Feb; 37(1):42-47. PubMed ID: 31612694
[TBL] [Abstract][Full Text] [Related]
14. Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial).
Fujisawa S; Ueda Y; Usuki K; Kobayashi H; Kondo E; Doki N; Nakao T; Kanda Y; Kosugi N; Kosugi H; Kumagai T; Harada H; Shikami M; Maeda Y; Sakura T; Inokuchi K; Saito A; Nawa Y; Ogasawara M; Nishida J; Kondo T; Yoshida C; Kuroda H; Tabe Y; Maeda Y; Imajo K; Kojima K; Morita S; Komukai S; Kawaguchi A; Sakamoto J; Kimura S
Int J Clin Oncol; 2019 Apr; 24(4):445-453. PubMed ID: 30421023
[TBL] [Abstract][Full Text] [Related]
15. Clinical roundtable monograph: Emerging treatment options for TKI-resistant chronic myelogenous leukemia.
Cortes J; Radich J; Mauro MJ
Clin Adv Hematol Oncol; 2012 Oct; 10(10 Suppl 19):1-16. PubMed ID: 23187745
[TBL] [Abstract][Full Text] [Related]
16. Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study.
Lee SE; Choi SY; Song HY; Kim SH; Choi MY; Park JS; Kim HJ; Kim SH; Zang DY; Oh S; Kim H; Do YR; Kwak JY; Kim JA; Kim DY; Mun YC; Lee WS; Chang MH; Park J; Kwon JH; Kim DW
Haematologica; 2016 Jun; 101(6):717-23. PubMed ID: 26888022
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Outcomes after Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease.
Yhim HY; Lee NR; Song EK; Yim CY; Jeon SY; Lee B; Kim JA; Kim HS; Cho EH; Kwak JY
Acta Haematol; 2016; 135(3):133-9. PubMed ID: 26535871
[TBL] [Abstract][Full Text] [Related]
18. Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia.
Atallah E; Schiffer CA; Weinfurt KP; Zhang MJ; Radich JP; Oehler VG; Pinilla-Ibarz J; Deininger MWN; Lin L; Larson RA; Mauro MJ; Moore JO; Ritchie EK; Shah NP; Silver RT; Wadleigh M; Cortes J; Thompson J; Guhl J; Horowitz MM; Flynn KE
BMC Cancer; 2018 Apr; 18(1):359. PubMed ID: 29609532
[TBL] [Abstract][Full Text] [Related]
19. Second-line Dasatinib Therapy Improved Compliance and Deep Molecular Responses in Imatinib-intolerant Chronic Myeloid Leukemia Patients.
Markovic U; Bulla A; Leotta S; Stella S; Consoli ML; TambÈ L; Conticello C; DI Raimondo F; Stagno F
Anticancer Res; 2020 Sep; 40(9):5313-5317. PubMed ID: 32878823
[TBL] [Abstract][Full Text] [Related]
20. Treatment-free remission in chronic myeloid leukemia.
Molica M; Naqvi K; Cortes JE; Paul S; Kadia TM; Breccia M; Kantarjian H; Jabbour EJ
Clin Adv Hematol Oncol; 2019 Dec; 17(12):686-696. PubMed ID: 31851157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]